Skip to main
ALLO
ALLO logo

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 35%
Hold 17%
Sell 4%
Strong Sell 0%

Bulls say

Allogene Therapeutics Inc's innovative approach to allogeneic T-cell therapy is underscored by promising clinical results, notably the impressive complete response (CR) rates of 100% and 82% in distinct patient categories, positioning the firm's cema-cel product competitively against approved autologous CAR-T therapies. The company's focus on logistically feasible and cost-effective cell therapies, combined with the potential for re-treatment and application in earlier treatment lines, suggests a robust pathway for accelerating patient uptake and meeting critical oncology needs. Furthermore, the anticipated review by the Data Safety Monitoring Board (DSMB) regarding event-free survival (EFS) analysis in early 2026 may yield insights that facilitate expedited development timelines, reinforcing the positive momentum in Allogene's clinical pipeline.

Bears say

Allogene Therapeutics Inc reported a net loss of $60 million, translating to an earnings per share (EPS) of ($0.28), indicating ongoing financial challenges exacerbated by the speculative nature of its clinical trials. The company's research and development expenses amounted to $44.9 million, which was lower than estimates, yet ongoing negative data from trials like UCART19 poses significant risks that could undermine investor confidence and delay potential approvals. Additionally, competition within the immuno-oncology sector could further diminish market share, heightening uncertainties around future revenue and elevating volatility in the company's stock price.

ALLO has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 35% recommend Buy, 17% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 23 analysts, ALLO has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.